Conference Call with Aurobindo Pharma Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.
Highlights: Revenue from Operations at INR 5,942 Cr decreased by 2.1% over corresponding period last year US formulations revenue grew by 6.9% on a YoY basis to INR 2,967.6 Cr Europe formulation revenue stood at INR 1,662 Cr, an increase of 9.7% over corresponding previous quarter Growth Markets declined by 13.5% YoY and grew by 17.3% QoQ to INR 386.3 Cr ARV revenue declined by 71.2% YoY to INR 145 Cr API revenue for the quarter was at INR 780.6 Cr vs. INR 829 Cr in the corresponding previous period EBIDTA before Forex and Other income stood at INR 1,186.7 Cr; EBITDA margin for the quarter was 20% Research & Development (R&D;) spend at INR 399 Cr, 6.7% of revenues (Q1 FY22: 6.3%) Received final approval for 7 ANDAs including 2 injectables and 1 505(b)(2) NDA from USFDA Net Profit stood at INR 696.7 Cr as against INR 711.4 Cr in the corresponding previous period Basic & Diluted EPS is INR 11.89 per share The Board declared an interim dividend of INR 1.50 per share Commenting on the Company’s performance, Mr. N. Govindarajan, Managing Director of the company said: “Business performance across most of the segments was robust, aided by gradual pick-up in demand and gradual market share gains. However, profitability was impacted by cost pressure on some of the key raw materials as well as higher logistic costs. We are leveraging the opportunity to streamline our working capital to improve cashflows and will continue to see the benefits of the same over the next few quarters. We are pleased with the steady progress in our complex generic product development and look forward to executing the same to enhance our business growth and profitability.” Result PDF